Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
Conditions
Prostate Cancer
Interventions
ASCENT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Cancer
Interventions
Curative Radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Bo Lu
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Conditions
Sarcoma
Interventions
PET/MR
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Not listed Not applicable Interventional Accepts healthy volunteers

Virtual Personalized Exercise Program for Lung Cancer Patients

NCT06540495
Conditions
Lung Cancer
Interventions
Salaso Virtual Exercise Program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Conditions
Cancer, Thoracic Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer
Interventions
Blood Specimen Collection, Stool Specimen Collection, Quality of Life (QOL) Questionnaires
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions
Chemoradiation
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
35
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more
Recruiting No phase listed Observational

Proton Therapy Patient Registry

NCT02986048
Conditions
Treatment With Proton Beam Radiation Therapy
Interventions
Proton Beam Therapy
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Pembrolizumab, Radiation Therapy, Axatilimab
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Cancer, Pharynx Cancer
Interventions
Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
Radiation · Drug
Lead sponsor
David M. Brizel, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
Interventions
Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
Procedure · Radiation
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Tongue Tumor, Tongue Cancer
Interventions
CT Scan, Experimental Oral Stent Device
Diagnostic Test · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Myxoid Liposarcoma of Soft Tissue
Interventions
dose reduction of preoperative radiotherapy in MLS
Radiation
Lead sponsor
The Netherlands Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Melanoma
Interventions
Observation, Radiation Therapy
Other · Radiation
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Interventions
LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy
Biological · Drug · Dietary Supplement + 2 more
Lead sponsor
CEL-SCI Corporation
Industry
Eligibility
18 Years and older
Enrollment
928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
5
States / cities
Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Interventions
Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Radiation Therapy, Metastatic Cancer
Interventions
Questionnaires, Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Other · Combination Product
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Jersey City, New Jersey • New Brunswick, New Jersey • Newark, New Jersey + 1 more
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma